Abstract GS5-00: Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials

Published on Feb 15, 2020in Cancer Research8.378
· DOI :10.1158/1538-7445.SABCS19-GS5-00
Rowan T. Chlebowski1
Estimated H-index: 1
Rowan T. Chlebowski80
Estimated H-index: 80
+ 14 AuthorsDorothy S. Lane47
Estimated H-index: 47
  • References (0)
  • Citations (2)
📖 Papers frequently viewed together
25 Citations
21 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Cited By2
#1Philipp Y. Maximov (University of Texas MD Anderson Cancer Center)H-Index: 10
#2Balkees Abderrahman (University of Texas MD Anderson Cancer Center)H-Index: 6
Last. Ross Han (U of C: University of Chicago)H-Index: 2
view all 16 authors...
High dose synthetic estrogen therapy was the standard treatment for advanced breast cancer for three decades until the discovery of tamoxifen. A range of substituted triphenylethylene synthetic estrogens and diethylstilbestrol (DES) were used. It is now known that low doses of estrogens can cause apoptosis in Long-Term Estrogen Deprived (LTED) breast cancer cells resistant to antiestrogens. This action of estrogen can explain the reduced breast cancer incidence in postmenopausal women over 60, t...
#1Kara L. Britt (University of Melbourne)H-Index: 26
#2Jack Cuzick (QMUL: Queen Mary University of London)H-Index: 121
Last. Kelly-Anne Phillips (University of Melbourne)H-Index: 40
view all 3 authors...
Despite decades of laboratory, epidemiological and clinical research, breast cancer incidence continues to rise. Breast cancer remains the leading cancer-related cause of disease burden for women, affecting one in 20 globally and as many as one in eight in high-income countries. Reducing breast cancer incidence will likely require both a population-based approach of reducing exposure to modifiable risk factors and a precision-prevention approach of identifying women at increased risk and targeti...